Literature DB >> 10211139

Review of recent clinical studies with olanzapine.

G D Tollefson1, A J Kuntz.   

Abstract

Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments. Clinical investigations employing olanzapine have demonstrated a number of potential therapeutic advantages in reference not only to placebo but also to contemporary drug standards in the management of psychosis. This paper reviews data on the pharmacokinetics, efficacy and safety of olanzapine, its benefits for quality of life, and economic aspects to assist clinicians in determining where they can usefully employ it.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211139

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  8 in total

1.  [What does olanzapine give us?].

Authors:  W Blanco López; M Seguí Díaz; J Arremberg Alarcón; A Castelló Sabaté
Journal:  Aten Primaria       Date:  2001-03-31       Impact factor: 1.137

Review 2.  Biotransformation of post-clozapine antipsychotics: pharmacological implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 3.  Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications.

Authors:  J M Russell; J A Mackell
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 4.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.

Authors:  Korbtham Sathirakul; Clark Chan; Leyan Teng; Richard F Bergstrom; Kwee Poo Yeo; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

6.  Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study.

Authors:  Yi-Lung Chen; Ting-Sheng Cheng; For-Wey Lung
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

7.  Breast enlargement associated with low dose olanzapine.

Authors:  Ashish Aggarwal; Ashish Khandelwal; Manish Jain; R C Jiloha
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

8.  Treatment-refractory schizophrenia.

Authors:  Asaf Caspi; Michael Davidson; Carol A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.